

COSA FCC Group Clinical Professional Day 2011

Date: Tuesday 23rd August 2011

Meeting: Familial Cancer – research and practice 22-26th August 2011.

Venue: Mantra on Salt Beach, Kingscliff NSW

Groups: kConFab, Australian Ovarian Cancer Study (AOCS), Australian Breast Cancer Family Study (ABCFS), Australian Colorectal Cancer Family Study (ACCF)

The annual “Familial Cancer – research and practice” meeting has been in existence for over 10 years and is the major meeting for clinical and research professionals focussed on Familial Cancer in Australia. It is always well attended by a variety of disciplines with wide representation from all States. It also attracts high quality international speakers, most of whom are well recognised as leaders in their fields. All the clinical professionals working in familial cancer consider this meeting as their national update meeting and attend it in preference to most other national meetings even though these might also include aspects of familial cancer research and practice, including the annual COSA meeting. It is the only meeting completely dedicated to familial cancer and provides a unique opportunity to have updates on current clinical practice for common familial syndromes, discuss issues of clinical controversy or “evidence-free zone” and network to establish/nurture clinician and research relationships.



It is most efficient to include the COSA FCC Group Clinical Professional Day within the August meeting as that will reach the largest number of familial cancer clinical and research professionals for professional development purposes as well as allow the most efficient advertisement of COSA membership to the specialty. The COSA name was prominently displayed on the speakers’ podium as well as included in the conference book as the co-sponsor of the CPD.

As well as reaching a wider group of familial cancer clinical and research professional than we could hope to achieve by holding our CPD at the annual COSA meeting, we are able to use the infrastructure of the kConFab meeting to arrange for all conference room hire, administration and use their international and national invited speakers where possible.

The Familial Cancer – research and practice meeting is advertised on the kConFab and other collaborative group websites and an update about the meeting is included in the kConFab newsletter that is distributed to all kConfab participants and members. The kConfab members are national and international users of the kConFab resource. Consequently the COSA support of this meeting is widely recognised. The meeting is also reported in local clinic newsletters that go to all FCC patients and referring doctors as well as State Cancer Councils (depending on State reporting practices). A summary of the meeting is included in the FCC annual report for COSA members.

FCC CPD Final Program August 23rd 2011:

9-9.10 Welcome and admin arrangements

9.10-10.10

Session 1. “Familial Cancer Clinical Practice in the guideline-free zone” (Chair Nick Pachter, WA)

- A) Clinical management of women in BRCA families: Issues and controversies. (Gillian Mitchell, VIC)
- B) Polyposis Syndromes– what to do when genotyping seems not informative (Finlay Macrae, VIC)
- C) Cancer screening in Li Fraumeni families (David Thomas, VIC)

Break 10.40-11.10

11.10 – 12.40

Session 2. Psychosocial aspects of risk-reducing surgery (Chair Nina Hallowell, UK)

- A) *I just did it for the kids*: Mothering in the context of living with an increased risk of ovarian cancer. Alison McEwan (NZ) – COSA funded
- B) Are women at high risk for serous gynaecological cancer (SGC) opting for risk-reducing salpingo-oophorectomy motivated by high levels of anxiety and risk perceptions? Bettina Meisser NSW – COSA funded
- C) Rehabilitating the sick role: post-surgical experiences of high risk women who undergo risk reducing mastectomy talk. Nina Hallowell, UK – kConFab funded

12.40 – 1.45 LUNCH

1.45– 2.45

Krystal Barter, NSW, Pink Hope update

Session 3 Rare tumours (Chair Nicola Poplowski, SA)

- A) Use of SDHB immunohistochemistry to identify germline mutations of SDH genes Anthony Gill NSW – COSA funded
- B) Dissecting genetic pathways in schwannomatosis and malignant rhabdoid tumour Elizabeth Algar NSW – COSA funded

2.45-3.15 – update of clinical issues from InSiGHT (Finlay Macrae)

3.15 – 3.45 Break

3.45 – 5.15

Session 4 Rebranding chemoprevention into “medical prevention”: Who should have it and who should prescribe it? (Chair – Christobel Saunders WA)

- A) Selecting women for breast cancer chemoprevention and what agents should be used? Jack Cuzick, UK – kConFab funded
- B) Tamoxifen and risk of contralateral breast cancer for *BRCA1* and *BRCA2* mutation carriers: a combined analysis from the Kathleen Cunningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), the international *BRCA1* and *BRCA2* carrier cohort study (IBCCS) and the Breast Cancer Family Registry (BCFR). Kelly-Anne Phillips, VIC
- C) When, and how, should we incorporate chemoprevention into our clinical management of familial colorectal cancer? John Burn, UK – kConFab funded

The CPD was evaluated by personnel from “The Centre for Genetics Education” based at the Royal North Shore Hospital SYDNEY. The CGE was established in 1989 as the education arm of the NSW Genetics service of NSW Health and is funded as a statewide service by NSW Health through Northern Sydney Central Coast Area Health Service. The evaluation was based on the evaluation sheets completed by attendees. The summary outcomes include:

Summary: The FCC day drew mostly strongly appreciative comments. The multi-disciplinary topics, relevance to clinical practice, excellence of speakers, time for questions/discussions and attention to time-keeping were cited as the main points of satisfaction. 200 registrants for the day.

Table 1: respondents

Geneticists/oncologists	8
Genetic counsellor	26
Familial cancer registry	3
Medical practitioner (other)	1
Cytogenetics	
Molecular genetics	1
Education	
Other	5
Surveys completed	44

Table 2: Interest and relevance of sessions

Interest	Nil response	Not	OK	High/Very high
Session 1. Familial Cancer Clinical Practice in the guideline free zone	1	0	3	40 (90.9%)
Session 2. Psychological aspects of risk-reducing surgery	1	1	5 (11.4%)	37 (84.1%)
Session 3. Rare tumours & updates (Pink Hope & InSIGHT)	2	2	11 (25.0%)	29 (65.9%)
Session 4. Rebranding chemoprevention into medical prevention. Who should have it?	5 (11.4%)	1	2	36 (81.8%)
Relevance				
Session 1. Familial Cancer Clinical Practice in the guideline free zone	1	0	3	40 (90.9%)
Session 2. Psychological aspects of risk-reducing surgery	1	0	5 (11.4%)	38 (86.4%)
Session 3. Rare tumours & updates (Pink Hope & InSIGHT)	1	5 (11.4%)	11 (25.0%)	28 (63.6%)
Session 4. Rebranding chemoprevention into medical prevention. Who should have it?	7	0	3	38 (86.4%)

Most liked about the day

- Multi-disciplinary topics
- Relevance to clinical practice
- Excellent speakers
- Good time keeping
- Time for questions/discussions
- Other (See complete report of comments OVER PAGE.)

Least liked about the day

- Psychosocial sessions (geneticists/oncologists)
- Hard chairs
- Other (See complete report of comments OVER PAGE.)

Any other comments on the day

- Great timekeeping
- Great day
- Maybe a survey re topics closer to kConfab 2012..
- Encourage more oncology/surgeons to come/discuss outcomes of research
- Other (See complete report of comments OVER PAGE.)

Overall, the program was appreciated by the vast majority of the audience and many made suggestions for content of the next meeting in August 2012. Planning for that CPD is almost complete.

Gillian Mitchell
Chair, COSA Familial Cancer Group